Relapsed/Refractory Multiple Myeloma: Defining Refractory Disease and Identifying Strategies to Overcome Resistance

Seminars in Hematology

Volumn 49, Issue SUPPL. 1, 2012, Pages

  Siegel, David S ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BETA CATENIN; BORTEZOMIB; BT 062; DEXAMETHASONE; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LENALIDOMIDE; M PROTEIN; MONOCLONAL ANTIBODY; PROTEIN P53; SILTUXIMAB; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; THALIDOMIDE; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; BONE DESTRUCTION; BONE MARROW; CANCER CELL; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CARCINOGENESIS; CELL INTERACTION; CELL MIGRATION; CHROMOSOME DELETION; DISEASE COURSE; DRUG TARGETING; GENE MUTATION; GENE TRANSLOCATION; GENETIC DIFFERENCE; GENOMICS; HUMAN; INTRACELLULAR SIGNALING; MALIGNANT TRANSFORMATION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENOMICS; PATIENT MONITORING; PLASMA CELL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; HUMANS; MULTIPLE MYELOMA; PROTEASE INHIBITORS; RECURRENCE;

EID: 84862658798     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.05.005     Document Type: Article

References (127)

1. McKenna R.W., Kyle R.A., Kuehl W.M. Plasma cell neoplasms. WHO classification of tumors of haematopoietic and lymphoid tissues 2008, 200-213. International Agency for Research on Cancer, Lyon, France. S.H. Swedlow, E. Campo, N.L. Harris (Eds.).
2. Altekruse S, Kosary C, Krapcho M, et al (eds). SEER cancer statistics review 1975-2007. National Cancer Institute. Bethesda, MD, . Based on November 2009 SEER data submission posted to the SEER Website, 2010. Accessed on March 19, 2012. http://seer.cancer.gov/csr/1975-2007/.
3. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473. International Myeloma Working Group.
4. Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009, 23:3-9.
5. Bladé J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115-1123.
6. Anderson K.C., Kyle R.A., Rajkumar S.V., Stewart A.K., Weber D., Richardson P. ASH/FDA Panel on Clinical Endpoints in Multiple Myeloma. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008, 22:231-239.
7. Laubach J.P., Mitsiades C.S., Mahindra A., et al. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw 2011, 9:1209-1216.
8. Durie B.G. New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. Clin Lymphoma Myeloma 2005, 6:181-190.
9. Harousseau J.L., Dreyling M. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v155-v157.
10. Bradwell A.R., Carr-Smith H.D., Mead G.P., Harvey T.C., Drayson M.T. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003, 361:489-491.
11. Mead G.P., Carr-Smith H.D., Drayson M.T., Morgan G.J., Child J.A., Bradwell A.R. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004, 126:348-354.
12. Dispenzieri A., Kyle R., Merlini G., et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009, 23:215-224. International Myeloma Working Group.
13. Hassoun H., Reich L., Klimek V.M., et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2006, 132:155-161.
14. Agarwal J.R., Matsui W. Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. Anticancer Agents Med Chem 2010, 10:116-120.
15. Shapiro-Shelef M., Calame K. Regulation of plasma-cell development. Nat Rev Immunol 2005, 5:230-242.
16. Martins G., Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol 2008, 26:133-169.
17. McHeyzer-Williams L.J., Driver D.J., McHeyzer-Williams M.G. Germinal center reaction. Curr Opin Hematol 2001, 8:52-59.
18. Sze D.M., Toellner K.M., García de Vinuesa C., Taylor D.R., MacLennan I.C. Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. J Exp Med 2000, 192:813-821.
19. Slifka M.K., Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998, 10:252-258.
20. Andersen N.F., Standal T., Nielsen J.L., et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow. Br J Haematol 2005, 128:210-217.
21. Huff C.A., Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol 2008, 26:2895-2900.
22. Brennan S.K., Matsui W. Cancer stem cells: controversies in multiple myeloma. J Mol Med (Berl) 2009, 87:1079-1085.
23. Ghosh N., Matsui W. Cancer stem cells in multiple myeloma. Cancer Lett 2009, 277:1-7.
24. Matsui W., Huff C.A., Wang Q., et al. Characterization of clonogenic multiple myeloma cells. Blood 2004, 103:2332-2336.
25. Matsui W., Wang Q., Barber J.P., et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008, 68:190-197.
26. Drewinko B., Alexanian R., Boyer H., Barlogie B., Rubinow S.I. The growth fraction of human myeloma cells. Blood 1981, 57:333-338.
27. Fujita N., Jaye D.L., Geigerman C., et al. MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 2004, 119:75-86.
28. Lee A.H., Iwakoshi N.N., Anderson K.C., Glimcher L.H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 2003, 100:9946-9951.
29. Carrasco D.R., Sukhdeo K., Protopopova M., et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007, 11:349-360.
30. Shapiro-Shelef M., Lin K.I., Savitsky D., Liao J., Calame K. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med 2005, 202:1471-1476.
31. Kyle R.A., Rajkumar S.V. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 2007, 139:730-743.
32. Bladé J., Rosiñol L., Cibeira M.T., de Larrea C.F. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 2008, 22:1651-1657.
33. Landgren O., Kyle R.A., Pfeiffer R.M., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009, 113:5412-5417.
34. Preston D.L., Kusumi S., Tomonaga M., et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 1994, 137:S68-S97.
35. Mester B., Nieters A., Deeg E., Elsner G., Becker N., Seidler A. Occupation and malignant lymphoma: a population based case control study in Germany. Occup Environ Med 2006, 63:17-26.
36. Demers P.A., Vaughan T.L., Koepsell T.D., et al. A case-control study of multiple myeloma and occupation. Am J Ind Med 1993, 23:629-639.
37. Fritschi L., Siemiatycki J. Lymphoma, myeloma and occupation: results of a case-control study. Int J Cancer 1996, 67:498-503.
38. Eriksson M. Rheumatoid arthritis as a risk factor for multiple myeloma: a case-control study. Eur J Cancer 1993, 29A:259-263.
39. Hakulinen T., Isomaki H., Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985, 78(1supplA):29-32.
40. Katusic S., Beard C.M., Kurland L.T., Weis J.W., Bergstralh E. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 1985, 78(1supplA):50-55.
41. Jorgensen C., Guerin B., Ferrazzi V., Bologna C., Sany J. Arthritis associated with monoclonal gammapathy: clinical characteristics. Br J Rheumatol 1996, 35:241-243.
42. Linet M.S., McLaughlin J.K., Harlow S.D., Fraumeni J.F. Family history of autoimmune disorders and cancer in multiple myeloma. Int J Epidemiol 1988, 17:512-513.
43. Landgren O., Zhang Y., Zahm S.H., Inskip P., Zheng T., Baris D. Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 2006, 15:2342-2347.
44. Montella M., Crispo A., Frigeri F., et al. HCV and tumors correlated with immune system: a case-control study in an area of hyperendemicity. Leuk Res 2001, 25:775-781.
45. Franceschi S., Lise M., Trépo C., et al. Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomarkers Prev 2011, 20:208-214.
46. Amara S., Dezube B.J., Cooley T.P., Pantanowitz L., Aboulafia D.M. HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients. Clin Infect Dis 2006, 43:1198-1205.
47. Pulik M., Genet P., Jary L., Lionnet F., Jondeau K. Acute myeloid leukemias, multiple myelomas, and chronic leukemias in the setting of HIV infection. AIDS Patient Care STDS 1998, 12:913-919.
48. Brown L.M., Linet M.S., Greenberg R.S., et al. Multiple myeloma and family history of cancer among blacks and whites in the U.S. Cancer 1999, 85:2385-2390.
49. Dhodapkar M.V., Geller M.D., Chang D.H., et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 2003, 197:1667-1676.
50. Dhodapkar M.V., Krasovsky J., Osman K., Geller M.D. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003, 198:1753-1757.
51. Anderson K.C., Carrasco R.D. Pathogenesis of myeloma. Annu Rev Pathol 2011, 6:249-274.
52. Basak G.W., Srivastava A.S., Malhotra R., Carrier E. Multiple myeloma bone marrow niche. Curr Pharm Biotechnol 2009, 10:345-346.
53. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007, 7:585-598.
54. Caers J., Van Valckenborgh E., Menu E., Van Camp B., Vanderkerken K. Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer 2008, 95:301-313.
55. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004, 5:221-230.
56. Roodman G.D. Pathogenesis of myeloma bone disease. J Cell Biochem 2010, 109:283-291.
57. Ribatti D., Nico B., Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006, 25:4257-4266.
58. Landowski T.H., Olashaw N.E., Agrawal D., Dalton W.S. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 2003, 22:2417-2421.
59. Hazlehurst L.A., Damiano J.S., Buyuksal I., Pledger W.J., Dalton W.S. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000, 19:4319-4327.
60. Hideshima T., Bergsagel P.L., Kuehl W.M., Anderson K.C. Advances in biology of multiple myeloma: clinical applications. Blood 2004, 104:607-618.
61. Jakob C., Sterz J., Zavrski I., et al. Angiogenesis in multiple myeloma. Eur J Cancer 2006, 42:1581-1590.
62. Zini J.M., Tobelem G. Angiogenesis and hematologic malignancy. Bull Cancer 2007, 94 Spec No:S241-S246.
63. Ribatti D., Vacca A. The role of microenvironment in tumor angiogenesis. Genes Nutr 2008, 3:29-34.
64. Roccaro A.M., Hideshima T., Raje N., et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006, 66:184-191.
65. Kline M., Donovan K., Wellik L., et al. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leuk Res 2007, 31:591-598.
66. Sanderson R.D., Epstein J. Myeloma bone disease. J Bone Miner Res 2009, 24:1783-1788.
67. Terpos E., Sezer O., Croucher P., Dimopoulos M.A. Myeloma bone disease and proteasome inhibition therapies. Blood 2007, 110:1098-1104.
68. Tian E., Zhan F., Walker R., et al. The role of Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
69. Terpos E., Dimopoulos M.A. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005, 16:1223-1231.
70. Oshima T., Abe M., Asano J., et al. Myeloma cells suppress bone formation by secreting a soluable Wnt inhinitor sFRP-2. Blood 2005, 106:3160-3165.
71. Mahindra A., Hideshima T., Anderson K.C. Multiple myeloma: biology of the disease. Blood Rev 2010, 24 Suppl 1:S5-S11.
72. Dewald G.W., Kyle R.A., Hicks G.A., Greipp P.R. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985, 66:380-390.
73. Gould J., Alexanian R., Goodacre A., Pathak S., Hecht B., Barlogie B. Plasma cell karyotype in multiple myeloma. Blood 1988, 71:453-456.
74. Sawyer J.R., Waldron J.A., Jagannath S., Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995, 82:41-49.
75. Drach J., Schuster J., Nowotny H., et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 1995, 55:3854-3859.
76. Flactif M., Zandecki M., Laí J.L., et al. Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia 1995, 9:2109-2114.
77. Zandecki M., Obein V., Bernardi F., et al. Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells. Br J Haematol 1995, 90:693-696.
78. Dimopoulos M.A., Terpos E. Multiple myeloma. Ann Oncol 2010, 21 Suppl 7. vii143-50.
79. Zhan F., Huang Y., Colla S., et al. The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028.
80. Smadja N.V., Fruchart C., Isnard F., et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 1998, 12:960-969.
81. Fonseca R., Bergsagel P.L., Drach J., et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23:2210-2221. International Myeloma Working Group.
82. Debes-Marun C.S., Dewald G.W., Bryant S., et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003, 17:427-436.
83. Chng W.J., Winkler J.M., Greipp P.R., et al. Ploidy status rarely changes in myeloma patients at disease progression. Leuk Res 2006, 30:266-271.
84. Avet-Loiseau H., Attal M., Moreau P., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007, 109:3489-3495.
85. Shaughnessy J.D., Zhan F., Burington B.E., et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109:2276-2284.
86. Stewart A.K., Bergsagel P.L., Greipp P.R., et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007, 21:529-534.
87. Fonseca R., Bailey R.J., Ahmann G.J., et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002, 100:1417-1424.
88. Keats J.J., Reiman T., Belch A.R., Pilarski L.M. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma 2006, 47:2289-2300.
89. Kuehl W.M., Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002, 2:175-187.
90. Bezieau S., Devilder M.C., Avet-Loiseau H., et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001, 18:212-224.
91. Chesi M., Bergsagel P.L. Many multiple myelomas: making more of the molecular mayhem. Hematology Am Soc Hematol Educ Program 2011, 2011:344-353.
92. Bergsagel P.L., Kuehl W.M. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005, 23:6333-6338.
93. Keats J.J., Fonseca R., Chesi M., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
94. Annunziata C.M., Davis R.E., Demchenko Y., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
95. Voorhees P.M., Chen Q., Small G.W., et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 2009, 145:481-490.
96. Bazzaro M., Lee M.K., Zoso A., et al. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006, 66:3754-3763.
97. Chen D., Cui Q.C., Yang H., Dou Q.P. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006, 66:10425-10433.
98. Chen D., Daniel K.G., Chen M.S., Kuhn D.J., Landis-Piwowar K.R., Dou Q.P. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol 2005, 69:1421-1432.
99. Ovaa H., Kessler B.M., Rolén U., Galardy P.J., Ploegh H.L., Masucci M.G. Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci U S A 2004, 101:2253-2258.
100. Soligo D., Servida F., Delia D., et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001, 113:126-135.
101. Landis-Piwowar K.R., Milacic V., Chen D., et al. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat 2006, 9:263-273.
102. Richardson P.G., Hideshima T., Anderson K.C. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer. Control 2003, 10:361-369.
103. Fisher R.I., Bernstein S.H., Kahl B.S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867-4874.
104. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
105. O'Connor O.A., Wright J., Moskowitz C., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005, 23:676-684.
106. Goy A., Younes A., McLaughlin P., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:667-675.
107. Lü S., Chen Z., Yang J., et al. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp Hematol 2008, 36:1278-1284.
108. Lü S., Yang J., Chen Z., et al. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line. Exp Hematol 2009, 37. 831-17.
109. Lü S., Yang J., Song X., et al. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther 2008, 326:423-431.
110. Oerlemans R., Franke N.E., Assaraf Y.G., et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008, 112:2489-2499.
111. Condorelli F., Gnemmi I., Vallario A., Genazzani A.A., Canonico P.L. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008, 153:657-668.
112. Peart M.J., Tainton K.M., Ruefli A.A., et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003, 63:4460-4471.
113. Hideshima T., Richardson P.G., Anderson K.C. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 2011, 10:2034-2042.
114. Hideshima T., Catley L., Raje N., et al. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 2007, 138:783-791.
115. Hideshima T., Catley L., Yasui H., et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, 107:4053-4062.
116. Voorhees P.M., Manges R.F., Sonneveld P., et al. A phase 2 multicenter study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Blood 2011, 118. abstract 3971.
117. Ikeda H., Hideshima T., Fulciniti M., et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009, 15:4028-4037.
118. Lutz R.J., Whiteman K.R. Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs 2009, 1:548-551.
119. Bjorklund C.C., Aukerman S.L., Lopez-Girona A., et al. Targeting the Wnt/{beta}-Catenin signaling pathway and CD44-mediated adhesion as a rational approach to overcome lenalidomide resistance in multiple myeloma. Blood 2011, 118. abstract 928.
120. Kuhn D.J., Wang H., Jones R.J., Bjorklund C.C., Orlowski R.Z. Blockade of IGF-1R with OSI-906 overcomes bortezomib-resistance in multiple myeloma. Blood 2011, 118. abstract 925.
121. Gu J.L., Li J., Zhou Z.H., et al. Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma. Biochem Biophys Res Commun 2012, 420:644-650.
122. Bazzi M., Badros A. Multiple myeloma: Implementing signaling pathways and molecular biology in clinical trials. Cancer Biol Ther 2010, 10:830-838.
123. Chapman M.A., Lawrence M.S., Keats J.J., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471:467-472.
124. Anderson K.C. The 39th David A. Karnofsky Lecture: Bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 2012, 30:445-452.
125. Richardson P.G., Schlossman R.L., Weller E., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063-3067.
126. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498. Assessment of Proteasome Inhibition for Extending Remission (APEX) Investigators.
127. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565-1571.